Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ranolazine plus Metoprolol vs Flecainide plus Metoprolol in Atrial Fibrillation
NCT03162120Phase 3Withdrawn
- Sponsor
- ELPEN
- Start
- Sep 2018
- Primary completion
- Dec 2018
- Modality
- Small Molecules
01
Overview
Phase 3, randomised trial of ranolazine in Atrial fibrillation (AFib) (2 arms), sponsored by ELPEN. Primary endpoint: Number of 1-year-recurrences. Planned start Sep 2018; status: withdrawn.
02
Drugs
ranolazine
03
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on NCT03162120.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03162120.